Format

Send to

Choose Destination
Int J Neuropsychopharmacol. 2015 Jul 28;19(2). pii: pyv084. doi: 10.1093/ijnp/pyv084.

Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.

Author information

1
Ambulatory Healthcare Services, SEHA Corporate, Abu Dhabi, UAE (Dr Karameh); Psychiatry Department, American University of Beirut Medical Center (Dr Khani). drkaramehwael@hotmail.com.
2
Ambulatory Healthcare Services, SEHA Corporate, Abu Dhabi, UAE (Dr Karameh); Psychiatry Department, American University of Beirut Medical Center (Dr Khani).

Erratum in

  • Erratum. [Int J Neuropsychopharmacol. 2016]

Abstract

BACKGROUND:

This open trial was conducted to evaluate the effectiveness of intravenous clomipramine (CMI) in refractory obsessive-compulsive disorder (OCD).

METHODS:

Thirty OCD poor responders to previous multiple trials of anti-obsessive medications were selected and admitted to the hospital. Severity of the illness and response to treatment were primarily assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). CMI was gradually administered intravenously for one week. All patients were thereafter switched to oral CMI with a maximum dose of 225 mg/day.

RESULTS:

The Y-BOCS total score mean at admission was in the severe range (24-31), and dropped on discharge and follow-ups to the moderate range (16-23). At discharge, 23 patients (76.7%) had a decrease in Y-BOCS ≥ 25% and were considered responders, while only 18 (60%) were still responders at 24 weeks. No relevant persistent side effects were reported.

CONCLUSION:

Intravenous clomipramine could be of benefit for severe OCD cases that have not adequately responded to several therapies, including oral clomipramine.

KEYWORDS:

clomipramine; intravenous clomipramine; obsessive-compulsive disorder; treatment-resistant OCD

PMID:
26221004
PMCID:
PMC4772819
DOI:
10.1093/ijnp/pyv084
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center